ClinicalTrials.gg
CompletedNCT00297778Updated Jun 9, 2014Results posted

Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms

A Phase 4 interventional study of Pramipexole and Placebo in Parkinson Disease and Depression, sponsored by Boehringer Ingelheim. Completed at 77 sites in 13 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-06-09.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
296
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
11th of 26
296 · median 224
Started
2006
with 4 others
Phase 4
10 of 26
none open now
Registered
5th of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 11th largest by enrollment, is one of 5 that started in 2006, is one of 10 in phase 4, and was the 5th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

Parkinsons Disease (PD) is caused by a decrease of dopamine in a particular part of the brain. Dopamine is a messenger substance (neurotransmitter) that is used by the cells of the brain (nerve cells) to control and harmonize muscle movements. Consequently, the main manifestations of the disease affect movement and include tremor, muscular rigidity, slowness in performing movements and loss of balance.

However, the disease affects also other, non motor functions and may cause other disorders, such as depression. Depression may be a reaction to the disability caused by the disease, but many studies show that depression is more common in PD than in other chronic debilitating illnesses. Moreover, there is also a biological explanation for the phenomenon: dopamine is also used in brain circuits involved in the experience of pleasure, and loss of pleasure in daily physical or social activity is one of the key manifestations of depression.

The objective of the study is to assess whether pramipexole, at doses approved for the treatment of PD symptoms, is more effective than placebo in resolving depressive symptoms in PD patients.

Also data on the safety of the product in the disease will be collected.

03

Conditions studied

  • Parkinson Disease
  • Depression
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 15-item Geriatric Depression Scale (GDS) > or = 5
  2. Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score on Question #3 > or = 2
  3. Folsteins (MMSE) score > 24
  4. Male or female patient with PD (UK PD Brain Bank criteria).
  5. Patients diagnosed with idiopathic PD, Stage I-III by the Modified Hoehn and Yahr Scale and optimally controlled PD symptoms .
  6. Male or female patients aged 30 - 80 years.
  7. Ability to provide written .
  8. Women of must have a negative serum beta-humanchoriongonadotropin (Beta-HCG) pregnancy test at the Screening visit unless surgically sterile or last menstruation >or = 12 months prior to signing informed consent.
  9. Women of childbearing potential must be using an accepted .
  10. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Previous history of allergic response, lack of efficacy or complications with pramipexole or its .
  2. History of suicidal attempts in the last twelve months; presence of suicidal tendencies/potential.
  3. Atypical PD syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases.
  4. History of PD stereotactic brain surgery.
  5. Surgery within 180 days of randomization that would negatively impact the patients participation in the study.
  6. History of active epilepsy within the past year.
  7. Current psychotherapy or behavior therapy while participating the trial
  8. Symptomatic orthostatic hypotension prior to randomization.
  9. Malignant melanoma or history of previously treated malignant melanoma.
  10. Patients who have received typical neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, selegiline or amphetamine derivatives within the past 3 months.
  11. Patients who have received dopamine agonists within the past 30 days
  12. Electroconvulsive therapy during the 90 days preceding the screening visit (Visit 1).
  13. Patients who are currently lactating.
  14. Participation in other drug studies or use of other investigational drugs within the previous 30 days prior to randomization.
  15. Any other laboratory assay abnormality, which could interfere with patient participation or interpretation of results, or could increase the risk for the patient
  16. Any other medical/psychiatric condition, which could interfere with patient participation or interpretation of results, or could increase the risk for the patient
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
296 participants (actual)

Study arms

  • Experimental
    pramipexole

    A daily dose of pramipexole 0.125 mg t.i.d.; titration-to-response up to 1.0 mg t.i.d.

    Drug: Pramipexole

  • Placebo comparator
    placebo

    Placebo (matching) tablets

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12

    The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change in BDI-IA Clinical Response (at Least 50% Reduction in Symptoms) at Week 12

    BDI clinical response was defined as a reduction of ≥50% from baseline

    Time frame: Week 12

  2. Change From Baseline in the Geriatric Depression Scale-Short Form (GDS-SF) (15-item Version) Total Score at Week 12

    The GDS measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 15 (worst symptoms)

    Time frame: Baseline and Week 12

  3. Change From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Week 12

    The SHAPS measures anhedonia (inability to experience pleasure) on an ordinal scale ranging from 0 (no anhedonia) to 14 (worst anhedonia)

    Time frame: Baseline and Week 12

  4. Change From Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) Part I Depression Score at Week 12

    The UPDRS part I depression score measures depression on an ordinal scale ranging from 0 (none) to 4 (sustained depression/suicidal thoughts)

    Time frame: Baseline and Week 12

  5. Change From Baseline in the UPDRS Part II Total Score at Week 12

    Unified Parkinson's Disease Rating Scale part II total score on FAS The UPDRS part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (normal) to 52 (worst symptoms)

    Time frame: Baseline and Week 12

  6. Change From Baseline in the UPDRS Part III Total Score at Week 12

    The UPDRS part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (normal) to 108 (worst symptoms)

    Time frame: Baseline and Week 12

  7. Change From Baseline in the UPDRS Part II+III Total Score at Week 12

    The UPDRS part II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (normal) to 160 (worst symptoms)

    Time frame: Baseline and Week 12

  8. Clinical Global Impressions of Global Improvement (CGI-I) at Week 12

    The CGI-I measures the overall improvement in the participants condition from baseline on an ordinal scale ranging from 1 (very much improved) to 7 (very much worse)

    Time frame: Week 12

  9. Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Week 12

    The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)

    Time frame: Baseline and Week 12

  10. Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Week 12

    This is a 5-item patient reported measure of health status developed for use in evaluating health and healthcare. It produces a numeric score for health status on which full health has a value of 1 and death has a value of 0. Euro-QOL describes health status in terms of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)

    Time frame: Baseline and Week 12

  11. Change From Baseline to End of Maintenance Phase in European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Pain Score at Week 12

    The VAS is a method used for the measurement of pain. The patient is asked to place a mark on an uncalibrated (usually 0 - 10 cm) line representing the patient's degree of general pain. The two extremities of the line were taken to represent 'no pain' and 'unbearable pain', respectively. VAS pain scores could range from 0 (no pain) to 100 (unbearable pain).

    Time frame: Baseline and Week 12

  12. Change From Baseline in the UPDRS Part I Total Score at Week 12

    The UPDRS part I total score measures depression on an ordinal scale ranging from 0 to 16. UPDRS Part I total scores could range from 0 to 16; where higher scores were indicative of worse symptoms.

    Time frame: Baseline and Week 12

  13. Change From Baseline in the UPDRS Part IV Total Score at Week 12

    The UPDRS Part IV measures motor complications (dyskinesia) and the total score could range from 0 to 23; where higher scores were indicative of worse symptoms.

    Time frame: Baseline and Week 12

  14. Abnormal Findings: Clinical Laboratory Evaluations (Biochemistry and Haematology)and Vital Signs

    Time frame: Baseline and Week 12

07

Results

Posted Sep 24, 2009

Participant flow

Participant flow — Overall Study
MilestonePlaceboPramipexole
Started152144
Completed133124
Not completed1920
Withdrew: Adverse event1610
Withdrew: Withdrawal by subject15
Withdrew: Lack of efficacy21
Withdrew: Non-compliant with trial protocol03
Withdrew: Other01

Outcome measures

PrimaryChange From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12

The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Score on scale
Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12
Score on scalePlaceboPramipexole
Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12-4 ± 0.5-5.9 ± 0.5
Statistical analysis
  • Placebo vs Pramipexole · ANCOVA · p = 0.0103 · Mean difference (net): -1.9 · 95% CI -3.4 to -0.5
SecondaryChange in BDI-IA Clinical Response (at Least 50% Reduction in Symptoms) at Week 12

BDI clinical response was defined as a reduction of ≥50% from baseline

Time frame:
Week 12
Reported as:
Number · participants
Change in BDI-IA Clinical Response (at Least 50% Reduction in Symptoms) at Week 12
participantsPlaceboPramipexole
Change in BDI-IA Clinical Response (at Least 50% Reduction in Symptoms) at Week 122738
Statistical analysis
  • Placebo vs Pramipexole · Regression, Logistic · p = 0.0535 · Odds ratio (or): 1.758 · 95% CI 0.992 to 3.115
SecondaryChange From Baseline in the Geriatric Depression Scale-Short Form (GDS-SF) (15-item Version) Total Score at Week 12

The GDS measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 15 (worst symptoms)

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Geriatric Depression Scale-Short Form (GDS-SF) (15-item Version) Total Score at Week 12
units on a scalePlaceboPramipexole
Change From Baseline in the Geriatric Depression Scale-Short Form (GDS-SF) (15-item Version) Total Score at Week 12-1.7 ± 0.3-2.5 ± 0.3
Statistical analysis
  • Placebo vs Pramipexole · ANCOVA · p = 0.0346 · Mean difference (net): -0.8 · 95% CI -1.5 to -0.1
SecondaryChange From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Week 12

The SHAPS measures anhedonia (inability to experience pleasure) on an ordinal scale ranging from 0 (no anhedonia) to 14 (worst anhedonia)

Time frame:
Baseline and Week 12
Reported as:
Median · units on a scale
Change From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Week 12
units on a scalePlaceboPramipexole
Change From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Week 120 (-2 to 0)0 (-2 to 0)
Statistical analysis
  • Placebo vs Pramipexole · Wilcoxon (Mann-Whitney) · p = 0.5244 · Mean difference (net): 0 · 95% CI -1 to 0
SecondaryChange From Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) Part I Depression Score at Week 12

The UPDRS part I depression score measures depression on an ordinal scale ranging from 0 (none) to 4 (sustained depression/suicidal thoughts)

Time frame:
Baseline and Week 12
Reported as:
Median · units on a scale
Change From Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) Part I Depression Score at Week 12
units on a scalePlaceboPramipexole
Change From Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) Part I Depression Score at Week 12-1 (-1 to 0)-1 (-2 to 0)
Statistical analysis
  • Placebo vs Pramipexole · van Elteren (country stratification) · p = 0.141 · Median difference (net): 0 · 95% CI 0 to 0
SecondaryChange From Baseline in the UPDRS Part II Total Score at Week 12

Unified Parkinson's Disease Rating Scale part II total score on FAS The UPDRS part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (normal) to 52 (worst symptoms)

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the UPDRS Part II Total Score at Week 12
units on a scalePlaceboPramipexole
Change From Baseline in the UPDRS Part II Total Score at Week 12-1.2 ± 0.3-2.4 ± 0.3
Statistical analysis
  • Placebo vs Pramipexole · ANCOVA · p = 0.003 · Mean difference (net): -1.2 · 95% CI -1.9 to -0.4
SecondaryChange From Baseline in the UPDRS Part III Total Score at Week 12

The UPDRS part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (normal) to 108 (worst symptoms)

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the UPDRS Part III Total Score at Week 12
units on a scalePlaceboPramipexole
Change From Baseline in the UPDRS Part III Total Score at Week 12-2.2 ± 0.5-4.4 ± 0.6
Statistical analysis
  • Placebo vs Pramipexole · ANCOVA · p = 0.0034 · Mean difference (net): -2.2 · 95% CI -3.7 to -0.7
SecondaryChange From Baseline in the UPDRS Part II+III Total Score at Week 12

The UPDRS part II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (normal) to 160 (worst symptoms)

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the UPDRS Part II+III Total Score at Week 12
units on a scalePlaceboPramipexole
Change From Baseline in the UPDRS Part II+III Total Score at Week 12-3.4 ± 0.7-6.8 ± 0.7
Statistical analysis
  • Placebo vs Pramipexole · ANCOVA · p = 0.0007 · Mean difference (net): -3.4 · 95% CI -5.4 to -1.5
SecondaryClinical Global Impressions of Global Improvement (CGI-I) at Week 12

The CGI-I measures the overall improvement in the participants condition from baseline on an ordinal scale ranging from 1 (very much improved) to 7 (very much worse)

Time frame:
Week 12
Reported as:
Median · units on a scale
Clinical Global Impressions of Global Improvement (CGI-I) at Week 12
units on a scalePlaceboPramipexole
Clinical Global Impressions of Global Improvement (CGI-I) at Week 123 (1 to 6)3 (1 to 6)
Statistical analysis
  • Placebo vs Pramipexole · Regression, Logistic · p = 0.006 · Odds ratio (or): 1.821 · 95% CI 1.187 to 2.794
SecondaryChange From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Week 12

The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)

Time frame:
Baseline and Week 12
Reported as:
Median · units on a scale
Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Week 12
units on a scalePlaceboPramipexole
Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Week 12-2.4 (-8.9 to 2.6)-3.3 (-8.9 to 0.3)
Statistical analysis
  • Placebo vs Pramipexole · van Elteren (country stratification) · p = 0.1925 · Median difference (net): -1.3 · 95% CI -3.3 to 0.8
SecondaryChange From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Week 12

This is a 5-item patient reported measure of health status developed for use in evaluating health and healthcare. It produces a numeric score for health status on which full health has a value of 1 and death has a value of 0. Euro-QOL describes health status in terms of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)

Time frame:
Baseline and Week 12
Reported as:
Median · units on a scale
Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Week 12
units on a scalePlaceboPramipexole
Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Week 120 (-0.06 to 0.12)0.07 (0 to 0.21)
Statistical analysis
  • Placebo vs Pramipexole · Wilcoxon rank sum (Van Elteren's test) · p = 0.0337 · Hodges-lehmann est of diff in medians: 0.04 · 95% CI 0 to 0.09
SecondaryChange From Baseline to End of Maintenance Phase in European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Pain Score at Week 12

The VAS is a method used for the measurement of pain. The patient is asked to place a mark on an uncalibrated (usually 0 - 10 cm) line representing the patient's degree of general pain. The two extremities of the line were taken to represent 'no pain' and 'unbearable pain', respectively. VAS pain scores could range from 0 (no pain) to 100 (unbearable pain).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mm
Change From Baseline to End of Maintenance Phase in European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Pain Score at Week 12
mmPlaceboPramipexole
Change From Baseline to End of Maintenance Phase in European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Pain Score at Week 12-3 ± 1.8-3.5 ± 1.9
Statistical analysis
  • Placebo vs Pramipexole · ANCOVA · p = 0.8471 · Mean difference (net): -0.5 · 95% CI -5.6 to 4.6
SecondaryChange From Baseline in the UPDRS Part I Total Score at Week 12

The UPDRS part I total score measures depression on an ordinal scale ranging from 0 to 16. UPDRS Part I total scores could range from 0 to 16; where higher scores were indicative of worse symptoms.

Time frame:
Baseline and Week 12
Reported as:
Median · units on a scale
Change From Baseline in the UPDRS Part I Total Score at Week 12
units on a scalePlaceboPramipexole
Change From Baseline in the UPDRS Part I Total Score at Week 12-1.0 (-1.0 to 0.0)-1.0 (-2.0 to 0.0)
Statistical analysis
  • Placebo vs Pramipexole · Wilcoxon rank sum (Van Elteren's test) · p = 0.1410 · Hodges-lehmann est of diff in medians: 0.0 · 95% CI 0.0 to 0.095% Confidence interval is Distribution-free Confidence Interval (Moses).
SecondaryChange From Baseline in the UPDRS Part IV Total Score at Week 12

The UPDRS Part IV measures motor complications (dyskinesia) and the total score could range from 0 to 23; where higher scores were indicative of worse symptoms.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the UPDRS Part IV Total Score at Week 12
units on a scalePlaceboPramipexole
Change From Baseline in the UPDRS Part IV Total Score at Week 12-0.2 ± 0.1-0.3 ± 0.1
Statistical analysis
  • Placebo vs Pramipexole · ANCOVA · p = 0.5231 · Mean difference (net): -0.1 · 95% CI -0.5 to 0.2
SecondaryAbnormal Findings: Clinical Laboratory Evaluations (Biochemistry and Haematology)and Vital Signs
Time frame:
Baseline and Week 12
Reported as:
Number · participants
Abnormal Findings: Clinical Laboratory Evaluations (Biochemistry and Haematology)and Vital Signs
participantsPlaceboPramipexole
Hypotension11
Orthostatic hypotension10

Adverse events

Collected over First drug intake up to 48 hours after the last drug intake. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo———
Pramipexole———
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPlaceboPramipexole
EndocarditisInfections and infestations0/1521/144
HyperlipidaemiaMetabolism and nutrition disorders0/1521/144
HallucinationPsychiatric disorders0/1521/144
Cerebral haemorrhageNervous system disorders0/1521/144
Cerebrovascular accidentNervous system disorders0/1521/144
SyncopeNervous system disorders0/1521/144
Cardiac failureCardiac disorders1/1521/144
ArthralgiaMusculoskeletal and connective tissue disorders0/1521/144
AnuriaRenal and urinary disorders0/1521/144
FallInjury, poisoning and procedural complications1/1521/144
Most frequent other events
Most frequent other events
EventPlaceboPramipexole
NauseaGastrointestinal disorders26/15224/144
DizzinessNervous system disorders9/15216/144
HeadacheNervous system disorders12/15216/144
SomnolenceNervous system disorders12/15215/144
DyskinesiaNervous system disorders4/15210/144
VertigoEar and labyrinth disorders4/15210/144
FatigueGeneral disorders9/1528/144
InsomniaPsychiatric disorders4/1528/144

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboPramipexoleTotal
Mean66.6 ± 9.967.4 ± 9.067 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPramipexoleTotal
Female7482156
Male7862140
08

Study locations

77 sites
  • 248.596.43003 Boehringer Ingelheim Investigational Site
    Graz, Austria
  • 248.596.43001 Boehringer Ingelheim Investigational Site
    Innsbruck, Austria
  • 248.596.43005 Boehringer Ingelheim Investigational Site
    Linz, Austria
  • 248.596.43004 Boehringer Ingelheim Investigational Site
    St. Pölten, Austria
  • 248.596.43002 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 248.596.35801 Boehringer Ingelheim Investigational Site
    Oulu, Finland
  • 248.596.3302B Centre Hospitalier du Pays d'Aix
    Aix en Provence cedex 1, France
  • 248.596.3302A Centre Hospitalier du Pays d'Aix
    Aix en Provence, France
  • 248.596.3306A Hôpital Pierre Wertheimer
    Bron cedex, France
  • 248.596.3308A Hôpital Gabriel Montpied
    Clermont Ferrand, France
  • 248.596.3309A Cabinet Médical
    Evreux, France
  • 248.596.3307A Hôpital Roger Salengro
    Lille cedex, France
  • 248.596.3307B Hôpital Roger Salengro
    Lille cedex, France
  • 248.596.3307C Hôpital Roger Salengro
    Lille cedex, France
  • 248.596.3303A Hôpital La Timone
    Marseille cedex 5, France
  • 248.596.3305A Hôpital du Haut Levêque
    Pessac cédex, France
  • 248.596.3305B Hôpital du Haut Levêque
    Pessac cédex, France
  • 248.596.3301A Hôpital Guillaume et René Laennec
    Saint Herblain, France
  • 248.596.49012 Boehringer Ingelheim Investigational Site
    Berlin-Steglitz, Germany
  • 248.596.49002 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.596.49013 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.596.49015 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.596.49003 Boehringer Ingelheim Investigational Site
    Bremerhaven, Germany
  • 248.596.49004 Boehringer Ingelheim Investigational Site
    Gera, Germany
  • 248.596.49001 Boehringer Ingelheim Investigational Site
    Karlsruhe, Germany
  • 248.596.49016 Boehringer Ingelheim Investigational Site
    Köln, Germany
  • 248.596.49005 Boehringer Ingelheim Investigational Site
    Marburg, Germany
  • 248.596.49014 Boehringer Ingelheim Investigational Site
    Mittweida, Germany
  • 248.596.49008 Boehringer Ingelheim Investigational Site
    München, Germany
  • 248.596.39008 Clinica Neurologica I Policlinico di Catania
    Catania, Italy
  • 248.596.39004 Neurologia Ospedale della Misericordia
    Grosseto, Italy
  • 248.596.39005 Clinica Neurologica Policlinico G. Martino
    Messina, Italy
  • 248.596.39009 Istituti Clinici di Perfezionamento
    Milano, Italy
  • 248.596.39003 Università degli studi di Napoli "Federico II"
    Napoli, Italy
  • 248.596.39001 Ospedale Civile S. Spirito, Università "G. D'Annunzio"
    Pescara, Italy
  • 248.596.39007 Clinica Neurologica Policlinico Tor Vergata
    Roma, Italy
  • 248.596.39006 Neurologia Ospedale Evangelico Valdese
    Torino, Italy
  • 248.596.31003 Jeroen Bosch Ziekenhuis, locatie WA
    's-Hertogenbosch, Netherlands
  • 248.596.31007 Afdeling neurologie
    Amsterdam, Netherlands
  • 248.596.31005 Ziekenhuis Gooi-Noord
    Blaricum, Netherlands
  • 248.596.31004 Amphia ziekenhuis, Locatie Molengracht
    Breda, Netherlands
  • 248.596.31002 Canisius-Wilhelmina Ziekenhuis
    Nijmegen, Netherlands
  • 248.596.31001 Maasland Ziekenhuis
    Sittard, Netherlands
  • 248.596.47002 Boehringer Ingelheim Investigational Site
    Arendal, Norway
  • 248.596.47004 Boehringer Ingelheim Investigational Site
    Lillehammer, Norway
  • 248.596.47003 Boehringer Ingelheim Investigational Site
    Sandvika, Norway
  • 248.596.40003 Boehringer Ingelheim Investigational Site
    Bucharest, Romania
  • 248.596.40004 Boehringer Ingelheim Investigational Site
    Bucharest, Romania
  • 248.596.40005 Boehringer Ingelheim Investigational Site
    Bucharest, Romania
  • 248.596.40001 Boehringer Ingelheim Investigational Site
    Cluj Napoca, Romania
  • 248.596.40002 Boehringer Ingelheim Investigational Site
    Iasi, Romania
  • 248.596.40006 Country Clinical Emergency Hospital
    Targu-Mures, Romania
  • 248.596.70001 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 248.596.70003 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 248.596.70002 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 248.596.70004 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 248.596.70005 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 248.596.27001 Boehringer Ingelheim Investigational Site
    Cape Town, South Africa
  • 248.596.27003 Boehringer Ingelheim Investigational Site
    Cape Town, South Africa
  • 248.596.27007 Boehringer Ingelheim Investigational Site
    Cape Town, South Africa
  • 248.596.27008 Boehringer Ingelheim Investigational Site
    Johannesburg, South Africa
  • 248.596.27004 Boehringer Ingelheim Investigational Site
    Pretoria, South Africa
  • 248.596.27006 Boehringer Ingelheim Investigational Site
    Richards Bay, South Africa
  • 248.596.34003 Hospital de Alcorcón. Departamento de Neurología
    Alcorcon (Madrid), Spain
  • 248.596.34001 Hospital Sta Creu i Sant Pau. Departamento de Neurología
    Barcelona, Spain
  • 248.596.34002 Hospital Clinic i Provincial. Departamento de Neurología
    Barcelona, Spain
  • 248.596.34005 Hosp. Univ. Vall d'Hebron. Departamento de Neurología
    Barcelona, Spain
  • 248.596.34007 Hosp Gral Univ Gregorio Marañón. Departamento de Neurología
    Madrid, Spain
  • 248.596.34004 Hospital General de Catalunya. Departamento de Neurología
    San Cugat del Valles (Barcelona), Spain
  • 248.596.46004 Boehringer Ingelheim Investigational Site
    Linköping, Sweden
  • 248.596.46001 Boehringer Ingelheim Investigational Site
    Stockholm, Sweden
  • 248.596.46002 Boehringer Ingelheim Investigational Site
    Stockholm, Sweden
  • 248.596.38004 Boehringer Ingelheim Investigational Site
    Donetsk, Ukraine
  • 248.596.38005 Boehringer Ingelheim Investigational Site
    Kharkiv, Ukraine
  • 248.596.38002 Boehringer Ingelheim Investigational Site
    Kiev, Ukraine
  • 248.596.38006 Boehringer Ingelheim Investigational Site
    Simferopol, Ukraine
  • 248.596.38003 Boehringer Ingelheim Investigational Site
    Vinnytzya, Ukraine
09

References and documents

Publications

  • Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Jun;9(6):573-80. doi: 10.1016/S1474-4422(10)70106-X. Epub 2010 May 7. PubMed 20452823 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006 and a primary completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2006
First posted
Mar 1, 2006
Start
Mar 2006
Primary completionActual
May 2008
Results first posted
Sep 24, 2009
Last update
Jun 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00297778
Responsible party
Sponsor
First posted
Mar 1, 2006
Start date
Mar 2006
Primary completion
May 2008
Results posted
Sep 24, 2009
Last update
Jun 9, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion